Oric Pharmaceuticals, Inc.
Business
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative oncology therapeutics designed to overcome cancer resistance mechanisms. The company's pipeline includes two lead programs: rinzimetostat, an allosteric PRC2 inhibitor licensed from Mirati for prostate cancer, and enozertinib, a brain-penetrant EGFR exon 20 inhibitor licensed from Voronoi for non-small cell lung cancer. Oric operates through internal R&D capabilities and clinical collaborations with partners including Johnson & Johnson and Bayer, focusing on three therapeutic areas: hormone-dependent cancers, precision oncology, and key tumor dependencies.
Summary from 10-K filed 2026-02-23
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 110 | 114 | 85 | 62 | 57 | |
| General and administrative | 33 | 29 | 26 | 25 | 22 | |
| Total operating expenses | 143 | 143 | 111 | 92 | 79 | |
| Loss from operations | −143 | −143 | −111 | −92 | −79 | |
| Other income, net | 14 | 15 | 10 | 3 | 156,000 | |
| Net loss | −129 | −128 | −101 | −89 | −79 | |
| Unrealized gain on investments | 407,000 | 121,000 | 2 | −1 | −72,000 | |
| Comprehensive loss | −129 | −128 | −99 | −90 | −79 | |
| Net loss per share, basic | −1.47 | −1.83 | −1.96 | −2.25 | −2.07 | |
| Net loss per share, diluted | −1.47 | −1.83 | −1.96 | −2.25 | −2.07 | |
| Weighted-average shares outstanding, basic | 88 | 70 | 51 | 40 | 38 | |
| Weighted-average shares outstanding, diluted | 88 | 70 | 51 | 40 | 38 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 46 | 59 | 23 | 67 | 226 | |
| Short-term investments | 236 | 197 | 185 | 139 | 11 | |
| Prepaid expenses and other current assets | 7 | 6 | 4 | 4 | 4 | |
| Total current assets | 288 | 262 | 213 | 210 | 241 | |
| Long-term investments | 111 | 0 | 27 | 22 | 43 | |
| Property and equipment, net | 2 | 3 | 3 | 3 | 2 | |
| Other assets | 7 | 9 | 10 | 12 | 12 | |
| Total assets | 409 | 274 | 252 | 247 | 299 | |
| Accounts payable | 4 | 2 | 944,000 | 1 | 2 | |
| Accrued liabilities | 17 | 23 | 20 | 14 | 13 | |
| Total current liabilities | 20 | 25 | 20 | 15 | 15 | |
| Other long-term liabilities | 4 | 6 | 7 | 9 | 11 | |
| Total liabilities | 25 | 31 | 28 | 25 | 26 | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 98,528,949 and 71,021,855 shares issued and outstanding at December 31, 2025 and 2024, respectively | 11,000 | 7,000 | 6,000 | 5,000 | 4,000 | |
| Additional paid-in capital | 1,076 | 806 | 659 | 558 | 518 | |
| Accumulated deficit | −692 | −563 | −435 | −334 | −245 | |
| Accumulated other comprehensive income | 786,000 | 379,000 | 258,000 | −1 | −103,000 | |
| Total stockholders' equity | 384 | 243 | 224 | 222 | 273 | |
| Total liabilities and stockholders' equity | 409 | 274 | 252 | 247 | 299 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 1 | 1 | 1 | 1 | 900,000 | |
| Stock-based compensation expense | 25 | 20 | 15 | 14 | 13 | |
| Accretion of discount on investments, net | −2 | −8 | −6 | −1 | 1 | |
| Prepaid expenses and other assets | 2 | 143,000 | 2 | 1 | 1 | |
| Accounts payable and accrued other liabilities | −7 | 2 | 3 | −1 | 3 | |
| Net cash used in operating activities | −111 | −113 | −86 | −75 | −60 | |
| Acquisitions of property and equipment | −712,000 | −1 | −849,000 | −2 | −939,000 | |
| Purchases of investments | −400 | −252 | −239 | −238 | −70 | |
| Maturities of investments | 253 | 275 | 197 | 131 | 229 | |
| Net cash (used in) provided by investing activities | −148 | 22 | −43 | −109 | 158 | |
| Proceeds from issuance of common stock and pre-funded warrants | 244 | 125 | 85 | 25 | 50 | |
| Issuance costs associated with financings | −2 | −168,000 | — | — | — | |
| Proceeds from issuance of common stock under ESPP | 1 | 1 | 826,000 | 545,000 | 0 | |
| Proceeds from stock option exercises | 2 | 631,000 | 59,000 | 79,000 | 986,000 | |
| Net cash provided by financing activities | 245 | 127 | 86 | 25 | 49 | |
| Net (decrease) increase in cash, cash equivalents and restricted cash | −14 | 36 | −43 | −159 | 148 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Oric Pharmaceuticals, Inc.'s CIK number?
Oric Pharmaceuticals, Inc.'s SEC CIK number is 0001796280 (1796280). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Oric Pharmaceuticals, Inc.'s SEC filings?
All of Oric Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Oric Pharmaceuticals, Inc. last report earnings?
Oric Pharmaceuticals, Inc. (ORIC) most recently filed an earnings 8-K with the SEC on May 4, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-203993). This is Oric Pharmaceuticals, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Oric Pharmaceuticals, Inc.'s most recent earnings 8-K?
Oric Pharmaceuticals, Inc.'s latest earnings 8-K (Item 2.02) was filed May 4, 2026 under accession 0001193125-26-203993. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Oric Pharmaceuticals, Inc.'s latest earnings 8-K →
Look up any company's CIK number →